Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 114

Results For "therapeutic"

1719 News Found

Alembic receives USFDA final approval for Fesoterodine Fumarate Extended-Release Tablets
Drug Approval | January 07, 2023

Alembic receives USFDA final approval for Fesoterodine Fumarate Extended-Release Tablets

Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, have an estimated market size of US$ 177 million for twelve months ending Sep 2022


Provention Bio appoints Rita Jain to Board of Directors
People | January 06, 2023

Provention Bio appoints Rita Jain to Board of Directors

Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co


Yaral Pharma launches diclofenac epolamine topical system 1.3%
News | January 05, 2023

Yaral Pharma launches diclofenac epolamine topical system 1.3%

Diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment


PharmaEssentia sets up a new R&D facility in the Boston Area
News | January 05, 2023

PharmaEssentia sets up a new R&D facility in the Boston Area

The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation


Briefs: Gland Pharma, Supriya Lifescience, Hindustan Unilever and Eugia Pharma
Drug Approval | January 05, 2023

Briefs: Gland Pharma, Supriya Lifescience, Hindustan Unilever and Eugia Pharma

Supriya Lifescience Limited has informed that the European Directorate for the Quality of Medicines (EDQM) has granted Attestation of Inspection (EU-GMP) for Lote API Facility, Ratnagiri, Maharashtra.


Matt Honan joins Emmes as VP & head of corporate development
People | January 05, 2023

Matt Honan joins Emmes as VP & head of corporate development

Honan will lead the company in identifying and executing acquisitions that complement Emmes’ existing strong federal government client base, expand its biopharma portfolio, enhance its technology offerings, and broaden its global reach


Themis Medicare launches Lenzetto for treatment of menopausal symptoms
News | January 04, 2023

Themis Medicare launches Lenzetto for treatment of menopausal symptoms

It ensures sufficient serum estradiol levels to alleviate menopausal symptoms


CNS Pharmaceuticals appoints Faith L. Charles as Chair of the Board of Directors
People | January 04, 2023

CNS Pharmaceuticals appoints Faith L. Charles as Chair of the Board of Directors

Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations


Polysciences announces new bioprocessing brand ‘Kyfora Bio’
News | January 03, 2023

Polysciences announces new bioprocessing brand ‘Kyfora Bio’

Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.


Cipla EU to invest € 15 million in Ethris
News | December 30, 2022

Cipla EU to invest € 15 million in Ethris

Cipla and Ethris partner for the development of mRNA-based therapies